Can we establish a hierarchy among trastuzumab biosimilar candidates?
Fiche publication
Date publication
juillet 2018
Journal
British journal of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry, Pr PIVOT Xavier
Tous les auteurs :
Pivot X, Petit T
Lien Pubmed
Résumé
The European patent for intravenous trastuzumab lapsed in 2017, and this stimulated research into a number of trastuzumab biosimilars. Quality assessment of their development and clinical results might enable establishment of a clinical hierarchy of these agents. This editorial will underline the key points for consideration when determining such an evaluation.
Référence
Br. J. Cancer. 2018 Jul 13;: